New top-line data from Athersys, Inc.’s Japanese partner Healios K.K.’s placebo-controlled Phase II/III TREASURE study with the stem cell therapy MultiStem (invimestrocel; HLCM051) in ischemic stroke showed evidence of therapeutic impact on multiple clinically relevant endpoints over one year.
Healios, Athersys Confident Despite Missed Japan Stroke Endpoint
Investors Much Less Upbeat
A missed primary endpoint in new top-line results from a Japanese trial with the stem cell therapy for stroke MultiStem hits Athersys and Japanese partner hard, casting a shadow over ongoing studies.
